+1 (347) 952-8676 info@curtiscoulter.com

The drug development model is in need of a drastic shakeup. COVID-19 has only accelerated this. Now more than ever is there a need to initiate innovative formulation, delivery and development approaches in order to improve bioavailability and therapeutic performance. In an overcrowded and highly regulated drug development marketplace. extended release formulation is still regarded as one of the most successful methods in ensuring drug approval, advancing it’s product lifecycle and ensuring it’s brought to market in a timely fashion.

It’s not hard to see why it’s a popular method for companies in commercializing their drug products. Extended-release formulation allows them the opportunity to make only slight alterations to an already approved drug and get continued market exclusivity for many years on approval. In addition to extending the life of an established high-revenue drug, new modified release techniques can also increase the bioavailability of a new drug, minimizing any side effects and aiding in the treatment of specialized conditions and diseases.

So the future looks bright for modified release technologies. New and innovative methods of improving drug mechanisms are coming into the fold more than ever and we’ll be covering the latest innovative delivery and formulation approaches, as well as giving regulatory guidance updates at the forthcoming 2020 Global Drug Bioavailability Enhancement Virtual Summit this December (9-10th).

Are you looking to improve the performance of your drug products?

Consider joining industry’s leading drug development specialists this December at the Virtual Global Drug Bioavailability Enhancement Summit. Hear from 30+ senior drug bioavailability pioneers and network with 100’s of senior drug development innovators and walk away with multiple new drug formulation and bioavailability enhancement approaches strategies in just 2 short days. Speakers include:

This industry-leading event will bring together key decision makers and innovators within this rapidly growing space. By attending this unique event, you will learn directly from industry’s leading experts and hear unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.

Why Consider Attending the 2020 Global Drug Bioavailability Enhancement Virtual Summit?

  • 25+ industry-led speaker faculty over 2 full days sharing innovative drug development take-home strategies
  • 14+ hours of networking sessions and breaks over two full days to learn from network with pharmaceutical and biotech senior formulation, development and delivery professionals
  • 100’s Senior Participants spanning pharma, biotech and specialty delivery & technology companies
  • Dynamic Tech Showcase Hall with multiple leading formulation development, excipient suppliers, delivery and modeling experts

Benefit from industry participation from Pfizer, Merck, Novartis, Bristol Myers Squibb, GlaxoSmithKline, Celgene, Johnson & Johnson, and many more controlled and modified drug release innovators. Consider joining us in this December to enhance your drug delivery and formulation capabilities, which will decrease time to market on your drug products. Secure your seat TODAY!

Pin It on Pinterest

Share This

Share this with a friend or colleague!